Entering text into the input field will update the search result below

ALX Oncology begins dosing in phase 2/3 trial of evorpacept in gastric cancer

Mar. 02, 2022 8:00 AM ETALX Oncology Holdings Inc. (ALXO)LLYBy: Ravikash, SA News Editor

Doctor doing research in lab during COVID-19

Morsa Images/DigitalVision via Getty Images

  • ALX Oncology (NASDAQ:ALXO) said the first patient was dosed in a phase 2/3 ASPEN-06 trial evaluating its drug evorpacept and Eli Lilly's (NYSE:LLY) Cyramza (ramucirumab), added to trastuzumab and paclitaxel to treat patients with HER2-positive

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.